Nivolumab plus ipilimumab with chemoradiation for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether adding immunotherapy (nivolumab and ipilimumab) to standard chemoradiation can improve treatment for cervical cancer. It may help by training the immune system to better target cancer cells while radiation and chemotherapy work in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman age 18 or older.
- Your cervical cancer must be adenocarcinoma or squamous cell, and in a stage such as IB2–IB3, IIB–IVA with lymph node involvement in the right situations.
- You cannot have had chemotherapy, immunotherapy (checkpoint inhibitors), or radiation for cervical cancer before starting this study.
- You must be able to do normal activities with little or no help (WHO/ECOG performance status 0–1).
- You must have at least one tumor spot on scans that has not been previously irradiated and is measurable for the study.
- You must not have had certain exclusions such as small-cell (neuroendocrine) cervical cancer, prior hysterectomy, or confirmed spread beyond the planned radiation area.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immune-boosting drugs (iparomlimab and tuvonralimab) combined with standard chemotherapy given before surgery for locally advanced cervical cancer. The goal is to shrink the cancer and improve survival chances.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This study tests whether adding immunotherapy to chemotherapy, then giving chemotherapy together with radiation, works better for advanced cervical cancer. It aims to improve cancer control and help people live longer, without major safety issues.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemoradiation for locally advanced cervical cancer caused by HPV. It may be an option for women with stage 3-4A disease or positive lymph nodes who have not had immunotherapy before.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
Hear when a new Uterine Cervical Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.